FUJIAN WANCHEN BIOTECHNOLOGY GROUP CO., LTD. Financials Fujian Wanchen Biotechnology Group Co., Ltd.
Equities
300972
CNE100004KH1
Fishing & Farming
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.32 CNY | -1.91% |
|
+3.21% | -24.56% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,848 | 5,807 | 4,882 | - | - |
| Enterprise Value (EV) 1 | 1,848 | 5,807 | 4,882 | 4,882 | 4,882 |
| P/E ratio | 39.1 x | -69.6 x | 26 x | 13.7 x | 9.19 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 0.62 x | 0.24 x | 0.2 x | 0.16 x |
| EV / Revenue | - | 0.62 x | 0.24 x | 0.2 x | 0.16 x |
| EV / EBITDA | - | - | 6.77 x | 3.22 x | 2.17 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | 9 x | 4.71 x | 3.5 x | 2.53 x |
| Nbr of stocks (in thousands) | 153,500 | 154,694 | 172,393 | - | - |
| Reference price 2 | 12.04 | 37.54 | 28.32 | 28.32 | 28.32 |
| Announcement Date | 4/18/23 | 4/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 9,294 | 20,486 | 23,962 | 30,054 |
| EBITDA 1 | - | - | 721.3 | 1,518 | 2,246 |
| EBIT 1 | - | -76.43 | 501.1 | 1,264 | 1,975 |
| Operating Margin | - | -0.82% | 2.45% | 5.28% | 6.57% |
| Earnings before Tax (EBT) 1 | - | -84.72 | 501.7 | 1,265 | 1,971 |
| Net income 1 | 47.77 | -82.93 | 190 | 358.7 | 535.1 |
| Net margin | - | -0.89% | 0.93% | 1.5% | 1.78% |
| EPS 2 | 0.3079 | -0.5395 | 1.090 | 2.070 | 3.080 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/18/23 | 4/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | -50.98 |
| Net margin | - |
| EPS 2 | -0.3320 |
| Dividend per Share | - |
| Announcement Date | 3/18/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -11.4% | 22.6% | 29.5% | 32.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | 4.170 | 6.010 | 8.090 | 11.20 |
| Cash Flow per Share 2 | - | 6.610 | 2.230 | 7.860 | 11.20 |
| Capex 1 | - | 201 | 71.7 | 147 | 1,195 |
| Capex / Sales | - | 2.17% | 0.35% | 0.61% | 3.98% |
| Announcement Date | 4/18/23 | 4/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
28.32
CNY
Average target price
28.67
CNY
Spread / Average Target
+1.24%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.56% | 689M | |
| +18.09% | 1.03B | |
| +19.72% | 845M | |
| 0.00% | 780M | |
| -6.97% | 394M | |
| +3.51% | 368M | |
| -23.87% | 302M | |
| -25.42% | 268M | |
| -11.59% | 267M | |
| -12.75% | 261M |
- Stock Market
- Equities
- 300972 Stock
- Financials Fujian Wanchen Biotechnology Group Co., Ltd.